Innovative Dutch liver cancer treatment gets EU approval
A new treatment for liver cancer developed by Utrecht University’s teaching hospital UMC has received the European CE mark for quality and safety, which means it can now be used throughout the EU.
The treatment uses tiny radioactive beads to attack liver tumours. The beads are injected into the patient’s blood stream and become trapped in the tiniest blood vessels, located in and around the liver tumours. This enables them to emit their radiation close to the tumour.
The treatment is being marketed by UMC spin off company Quirem Medical. The treatment has been in development for 15 years.
‘Because they show up on MRI scans and SPECT-CT, these microspheres can be tracked, allowing customised treatment for each individual patient,’ Quirem founder Frank Nijsen is quoted as saying by the European Pharmaceutical Review. ‘Now that we have been awarded CE marking, patients all over Europe can benefit.’
Thank you for donating to DutchNews.nl.
We could not provide the Dutch News service, and keep it free of charge, without the generous support of our readers. Your donations allow us to report on issues you tell us matter, and provide you with a summary of the most important Dutch news each day.
Make a donation